Literature DB >> 26135008

Intestinal Absorption and Metabolism of Epimedium Flavonoids in Osteoporosis Rats.

Jing Zhou1, Yi Hua Ma1, Zhong Zhou1, Yan Chen2, Ying Wang1, Xia Gao1.   

Abstract

Herba Epimdii is a traditional Chinese medicine used to treat osteoporosis. Its main pharmacological ingredients are flavonoids. In previous studies conducted in healthy animals, we showed that epimedium flavonoids could be hydrolyzed into secondary glycosides or aglycon by intestinal flora or enzymes, thereby enhancing their absorption and antiosteoporosis activity. To study the medicine in the pathologic state, epimedium flavonoids were incubated with intestinal mucosa and feces in vitro and intestinal perfusion in situ to explore the differences in absorption and metabolism between sham and osteoporosis rats. For osteoporosis rats, the hydrolysis rates of icariin, epimedin A, epimedin B, and epimedin C incubated with intestinal flora for 1 hour were reduced by 0.19, 0.26, 0.19, and 0.14, respectively, compared with that in sham rats. Hydrolysis rates were reduced by 0.21, 0.24, 0.08, and 0.31 for icariin, epimedin A, epimedin B, and epimedin C incubated with duodenal enzymes for 1 hour and by 0.13, 0.09, 0.07, and 0.47 for icariin, epimedin A, epimedin B, and epimedin C incubated with jejunum enzymes, respectively, compared with the sham group. In addition, the apparent permeability coefficient and elimination percentage of the four epimedium flavonoids in the duodenum, jejunum, ileum, and colon decreased by 29%-44%, 32%-50%, 40%-56%, and 27%-53% compared with that in sham rats, respectively. The main metabolites of the four epimedium flavonoids were the same for the two groups after intestinal perfusion, or flora and enzyme incubation. In conclusion, the amount and activity of intestinal flora and enzymes changed in ovariectomized rats, which affected the intestinal absorption and hydrolysis of epimedium flavonoids whose structures contain 7-glucose.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26135008     DOI: 10.1124/dmd.115.064386

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?

Authors:  Hollie I Swanson
Journal:  Drug Metab Dispos       Date:  2015-08-10       Impact factor: 3.922

2.  Influence of Nutritional Status on the Absorption of Polyphyllin I, an Anticancer Candidate from Paris polyphylla in Rats.

Authors:  Feng-Ling Yu; Wei-Liang Gong; Fang-Jiang Xu; Jun-Wen Wu; Shailendra Shakya; He Zhu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

3.  Metabolite Profiling, Pharmacokinetics, and In Vitro Glucuronidation of Icaritin in Rats by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry.

Authors:  Beibei Zhang; Xiaoli Chen; Rui Zhang; Fangfang Zheng; Shuzhang Du; Xiaojian Zhang
Journal:  J Anal Methods Chem       Date:  2017-07-10       Impact factor: 2.193

Review 4.  Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota.

Authors:  Ming Lyu; Yue-Fei Wang; Guan-Wei Fan; Xiao-Ying Wang; Shuang-Yong Xu; Yan Zhu
Journal:  Front Microbiol       Date:  2017-11-08       Impact factor: 5.640

Review 5.  Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review.

Authors:  Róbert Szabó; Csaba Pál Rácz; Francisc Vasile Dulf
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

Review 6.  Herbal Medicine, Gut Microbiota, and COVID-19.

Authors:  Ziqi Chen; Yiwen Lv; Huachong Xu; Li Deng
Journal:  Front Pharmacol       Date:  2021-07-07       Impact factor: 5.988

7.  Dual effects of baicalin on osteoclast differentiation and bone resorption.

Authors:  Xuanyuan Lu; Wei He; Wanlei Yang; Jianlei Li; Weiqi Han; Qian Liu; Tan Zhang; Jiawei Jiang; An Qin; Yu Qian
Journal:  J Cell Mol Med       Date:  2018-07-16       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.